This finding is highly consistent with our conclusion that “the combined detection of CA50, CA242, and SAA optimizes the assessment of pancreatic cancer prognosis.” Together, these findings reinforce the applicability and superiority of using combined biomarkers over single indicators in the diagnosis and treatment of PC. The gene discussed is SAA1; the disease is pancreatic neoplasm.